晚期转移性去势抵抗性前列腺癌患者接受重复177Lu-前列腺特异性膜抗原617放射配体治疗的长期生存与优异反应
Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · Clin Nucl Med · 2018-01-01
文中指出177Lu-PSMA-617放射配体治疗在转移性去势抵抗性前列腺癌中高效且安全,似可延长无进展生存期和总生存期。
要点
- 77岁经重度预处理的转移性去势抵抗性前列腺癌患者接受两个疗程177Lu-PSMA-617治疗,每疗程4个周期。
- 177Lu-PSMA-617放射配体治疗在转移性去势抵抗性前列腺癌中高效且安全,似可延长无进展生存期和总生存期。
核心结论
- 177Lu-PSMA-617放射配体治疗在转移性去势抵抗性前列腺癌中高效且安全,似可延长无进展生存期和总生存期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiolabeled ligands targeting prostate-specific membrane antigen (PSMA) are currently being established. Prostate-specific membrane antigen radioligand therapy with Lu-PSMA-617 is a promising treatment in metastasized castration-resistant prostate cancer with high efficacy and safety and seems to prolong progression-free survival and overall survival. We present Ga-PSMA PET/CT images during and after 2 therapy courses, including each 4 cycles of Lu-PSMA-617, and prostate-specific antigen-level history of a 77-year-old heavily pretreated patient with metastasized castration-resistant prostate cancer.
来源:Clin Nucl Med,查看原文。版权归原作者所有。
引用
- Roll W, Bräuer A, Weckesser M, et al. Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer. Clin Nucl Med. 2018. PMID: 30036254. doi:10.1097/RLU.0000000000002212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。